No Data
No Data
No Data
No Data
No Data
艾美疫苗:2023年度報告
Futu NewsApr 25 05:12 ET · Announcements
Would AIM Vaccine (HKG:6660) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Simply Wall StApr 19 18:31 ET
Emmy Vaccines received controlling shareholder Zhou Yan to continue to increase his shareholding
Le Méridien Vaccine (06660) issued an announcement. The board of directors of the company received a notice from Zhou Yan (Chairman of the Board of Directors, Executive Director, CEO and controlling shareholder of the Company) that Zhou Yan will continue to further increase the company's H shares (“this increase”) through the open market from January 12, 2024 to April 15, 2024. From November 14, 2023 to April 15, 2024, Zhou Yan has continued to increase her H shares in the company with a total of HK$10,420,212.00 through the open market, and it is not ruled out that she will continue to increase her shares in due course. As of the date of this announcement
新浪港股Apr 18 21:04 ET
Gelonghui Announcement Selection (HK Stock) | Ideal Automobile-W (02015.HK) Officially Launches Family 5-Seater Luxury SUV - Ideal L6
Ideal Automobile-W (02015.HK) officially released the family's five-seater luxury SUV - Ideal L6
Gelonghui FinanceApr 18 11:16 ET
Le Méridien Vaccine (06660.HK) Voluntary Announcement: Controlling Shareholder Continues to Further Increase H Shares
Gelonghui, April 18, 丨 Le Méridien Vaccine (06660.HK) announced that the company's board of directors received a notice from Zhou Yan (Chairman of the Board, Executive Director, CEO and controlling shareholder of the company). Zhou Yan continued to further increase the company's H shares through the open market from January 22, 2024 to April 18, 2024. From November 14, 2023 to April 18, 2024, Zhou Yan has continued to increase her H shares in the company through the open market with total capital of HK$10,420,212.00, and it is not ruled out that she will continue to increase her shares in due course. As of this announcement
Gelonghui FinanceApr 18 07:49 ET
Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3%
Aim Vaccine (HKG:6660) submitted pre-applications for clinical trials for two vaccines on Thursday, according to two separate Hong Kong bourse filings on the same day. These include the quadrivalent i
MT NewswiresMar 28 01:28 ET
No Data
No Data